Endometrial Intraepithelial Neoplasia: A Precancerous Condition

Endometrial intraepithelial neoplasia, commonly abbreviated EIN, is a precancerous change in the lining of the uterus that carries a meaningful risk of progressing to endometrial cancer. It is not cancer itself, but it signals that a clonal population of abnormal cells has established itself in the endometrium, and the risk of finding a coexisting cancer at the time of diagnosis can be surprisingly high. Understanding what EIN means for your body, how doctors find and classify it, and what treatment looks like is more nuanced than a simple “watch and wait” or “get surgery” binary.

What EIN Actually Is

The endometrium is the tissue that lines the inside of the uterus. Every menstrual cycle, it thickens in response to hormones and then sheds. EIN develops when a group of glands within that lining begins to grow abnormally, crowding out the surrounding tissue and showing cellular changes that distinguish them from normal endometrium. The diagnostic criteria include glands that are architecturally crowded (more gland than surrounding stroma), cells that look cytologically different from the normal background tissue, and a lesion that measures at least 1 mm across.¹ That last point about size matters because pathologists need to carefully exclude look-alikes, such as benign polyps or reactive changes, that can mimic EIN under a microscope.

What makes EIN distinct from run-of-the-mill endometrial thickening is that it represents a clonal expansion, a single population of genetically altered cells growing as a discrete focus. One study found that EIN lesions carry a long-term cancer risk roughly 45 times greater than that of benign endometrial hyperplasia.² That enormous gap in risk is precisely why pathologists need to distinguish EIN from harmless overgrowth.

How Naming Has Changed Over the Years

If you look at older pathology reports, you might see terms like “simple hyperplasia,” “complex hyperplasia,” or “atypical hyperplasia.” Those come from the older World Health Organization classification, which divided endometrial overgrowth into four categories based on somewhat subjective microscopic features. The problem was that different pathologists looking at the same tissue slide often disagreed about which category a sample fell into, which made it hard to predict who was actually at risk for cancer.

The EIN classification system was developed as a more reproducible alternative, using objective criteria like the gland-to-stroma ratio and cytologic demarcation from background tissue. The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology have stated that the EIN classification is superior to the older WHO system for categorizing endometrial hyperplasia.³ When the WHO updated its classification in 2014, it essentially merged the two approaches, creating a simplified two-tier system: benign hyperplasia on one side, and atypical hyperplasia/EIN on the other. So if your pathology report says “atypical hyperplasia/EIN,” that is the current standard terminology, and it flags a lesion that deserves serious clinical attention.

How High Is the Cancer Risk

This is the question most people diagnosed with EIN ask first, and the honest answer is that the numbers are higher than many expect. When researchers look at women who undergo hysterectomy after an EIN biopsy diagnosis, a substantial fraction turn out to already have cancer in the removed uterus. One study found that about 15% of women with an EIN biopsy had a concurrent cancer that the biopsy had missed.⁴ Other surgical series report even higher figures. A study of women who went on to hysterectomy after an EIN diagnosis found that roughly 41% had endometrial cancer on final pathology.⁵ Another surgical cohort reported nearly half had cancer at the time of their procedure.⁶

The wide range across studies reflects differences in which patients were studied. The higher percentages tend to come from surgical series, where the women included had already been selected for hysterectomy, often because doctors suspected something more serious. The lower figures come from broader cohorts that include women managed without surgery. A meta-analysis pooling data on women with atypical hyperplasia found the rate of developing endometrial cancer was about 8% per year for those who were followed over time rather than operated on immediately.⁷ Either way, these are not trivial numbers, and they explain why EIN is treated with urgency.

Who Gets EIN and Why

The single biggest driver is prolonged exposure to estrogen without the balancing effect of progesterone. In a normal menstrual cycle, estrogen makes the endometrium grow during the first half, and progesterone stabilizes and then helps shed it in the second half. When that balance tips toward estrogen dominance, the lining keeps growing without the usual checks, creating the conditions for abnormal clones to take hold.

Several common situations create that hormonal imbalance:

Obesity: Fat tissue produces estrogen through a process called aromatization. Women with obesity face a two- to four-fold higher risk of developing EIN and endometrial cancer compared to those at a normal weight, driven by hormonal shifts, insulin resistance, and chronic low-grade inflammation.⁸
Polycystic ovary syndrome (PCOS): Women with PCOS often do not ovulate regularly, meaning they produce estrogen but little progesterone for months at a time.
Estrogen-only hormone therapy: Taking estrogen replacement without a progestin, particularly around menopause, directly mimics the unopposed estrogen scenario.
Tamoxifen use: This breast cancer medication acts like estrogen on the uterine lining, even though it blocks estrogen in breast tissue.

Epidemiological research confirms that these overlapping causes, including metabolic dysfunction and extended unopposed estrogen exposure, account for the majority of endometrial hyperplasia cases.⁹

How EIN Is Found

Most women with EIN come to medical attention because of abnormal uterine bleeding, either unusually heavy periods, bleeding between periods, or any vaginal bleeding after menopause. Postmenopausal bleeding gets particular attention because the endometrium should be thin and inactive after menopause.

Ultrasound is usually the first step. Research using standardized ultrasound criteria has shown that when the endometrial lining measures less than 3 mm, the chance of finding cancer or EIN is essentially zero.¹⁰ That is reassuring for the many women with postmenopausal bleeding whose lining turns out to be thin. But ultrasound alone cannot definitively diagnose EIN. A study focused specifically on the sonographic appearance of EIN found that endometrial thickness ranged anywhere from 2 to 90 mm, and while the presence of polyps and the pattern of bleeding helped predict which cases were more likely to harbor cancer, ultrasound served more as a triage tool than a definitive diagnostic one.¹¹

A tissue sample is required for diagnosis. The most common office-based method is a Pipelle biopsy, a thin flexible tube inserted through the cervix to suction out a small strip of endometrial tissue. One large study found that Pipelle biopsy achieved about 89% sensitivity and 100% specificity for detecting endometrial cancer, with an overall diagnostic accuracy near 99% for malignancy.¹² The catch is that about a quarter of samples in that study were inadequate, meaning not enough tissue was obtained. When an office biopsy fails or comes back inconclusive, the next step is typically a hysteroscopy with dilation and curettage, where a camera is placed inside the uterus and tissue is sampled under direct visualization.

What Happens Under the Microscope

Diagnosing EIN requires more than just seeing that glands are crowded. The pathologist looks for a distinct population of glands whose cells look different from the normal surrounding endometrium. That internal comparison is key: the abnormal area should stand out from its neighbors in terms of cell size, shape, and staining pattern. This cytologic “demarcation” is what separates a true precancerous clone from benign overgrowth, where the glands may be plentiful but still look like normal endometrium.²

Molecular markers can add another layer of certainty. The most studied is PTEN, a tumor suppressor gene that is lost in a majority of endometrial precancers and cancers. One landmark study found PTEN mutations in 55% of precancers and 83% of endometrial cancers, while no normal endometrial samples showed these mutations.¹³ When PTEN loss is combined with the EIN morphologic diagnosis, predictive power for cancer progression increases substantially, with specificity rising from 85% for EIN alone to 93% when PTEN is factored in.¹⁴

PTEN is far from the only marker involved. A study examining a panel of immunohistochemical markers in EIN found that Pax2 was the most frequently abnormal marker, altered in about 81% of cases, followed by PTEN at about 51% and β-catenin at roughly 48%.¹⁵ Using a combination of three markers (Pax2, PTEN, and β-catenin) captured virtually all precancerous cases, offering pathologists a more reliable toolkit for borderline biopsies.

Surgical Treatment

For women who have completed childbearing or who are postmenopausal, hysterectomy is the standard recommendation. Removing the uterus accomplishes two things at once: it treats the precancerous lesion and it provides a definitive answer about whether cancer is already present, something a small biopsy can miss. The American College of Obstetricians and Gynecologists states that total hysterectomy is the appropriate treatment for EIN when clinically suitable, as it provides definitive assessment of possible concurrent carcinoma.

The procedure is usually a total hysterectomy (removal of the uterus and cervix). Whether the ovaries are also removed depends on the patient’s age, menopausal status, and other risk factors. In most cases of early-stage disease, the cancers found at hysterectomy after an EIN diagnosis are low-grade and minimally invasive, which means they carry a good prognosis.

Progestin Therapy as an Alternative

Not every woman with EIN proceeds straight to surgery. Younger women who want to preserve their fertility, as well as older women who are poor surgical candidates, can be treated with progestin therapy. The logic is straightforward: since EIN develops under the influence of unopposed estrogen, delivering high-dose progesterone counteracts that stimulus and can cause the abnormal tissue to regress.

Two main delivery methods exist: oral progestins (pills like medroxyprogesterone acetate or megestrol acetate) and the levonorgestrel-releasing intrauterine device (LNG-IUD), a hormonal IUD that delivers progestin directly to the uterine lining. A systematic review and meta-analysis comparing the two found that within 12 months, the complete response rate was about 82% with oral progestins and about 95% with the LNG-IUD.¹⁶ After the authors removed statistical outliers, those numbers tightened to 86% and 96%, respectively.

There is a trade-off, though. Oral progestins tend to achieve faster initial responses, but the LNG-IUD appears to produce more durable results. A multicenter retrospective study found that while oral progestins had higher complete response rates at 3 and 6 months, the recurrence rate was significantly higher in the oral group compared to the IUD group over longer follow-up.¹⁷ A separate large analysis reported that women treated with systemic progestins eventually needed hysterectomy about 36% of the time, compared to about 23% of those treated with the progestin-releasing IUD.¹⁸ The rate of eventually being diagnosed with uterine cancer was roughly 10% in the oral progestin group and about 8% in the IUD group, a difference that was not statistically significant but hints at the general pattern of the IUD offering slightly better long-term outcomes.

Fertility Preservation

For women diagnosed with EIN in their reproductive years who want to become pregnant, progestin therapy is the standard fertility-sparing approach. A systematic review of 29 studies covering over a thousand women found that about 83% achieved complete remission with various progestin regimens.¹⁹ Pregnancy rates among those who achieved remission and attempted conception ranged from about 56% to 63% depending on the specific treatment used. Live birth rates were encouraging, reaching roughly 69% to 81% in most treatment groups.

The important caveat is that remission does not mean the story is over. Recurrence rates after fertility-sparing treatment are high, often cited between 30% and 50% in the years following initial response. Most reproductive endocrinologists recommend attempting pregnancy as soon as remission is confirmed and, once childbearing is complete, proceeding with hysterectomy to eliminate the ongoing risk.

Weight loss can influence outcomes for overweight patients undergoing fertility-sparing treatment. A study of overweight women found that those who lost more than 15% of their body fat mass had a lower recurrence rate, and those who achieved meaningful reductions in visceral fat also had slightly higher pregnancy rates.²⁰ This fits with the broader understanding that excess body fat fuels the hormonal environment that drives EIN in the first place.

Monitoring After Treatment

Whether you undergo hysterectomy or medical management, follow-up is essential. For women treated with progestins, guidelines from multiple international bodies recommend repeat endometrial biopsies every three months until two consecutive negative results are obtained. After that, the interval can lengthen to every six months for a period of years, then annually.²¹ The minimum treatment duration recommended by some guidelines is six months, even if the biopsy normalizes before then. A premature stop in progestin therapy is one of the most common reasons for recurrence.

For women who have had a hysterectomy for EIN and whose final pathology shows no cancer, extensive long-term surveillance is generally not needed. However, if the hysterectomy specimen reveals an unexpected cancer, the management plan shifts to oncologic follow-up based on the cancer’s stage and grade.

Racial Disparities in Treatment

Access to guideline-recommended care is not equal across all groups. A study examining treatment patterns among postmenopausal women with EIN found a significant racial disparity: non-Hispanic Black women were less likely to undergo surgical management compared to non-Hispanic White women. That gap persisted even after the researchers adjusted for clinical factors like age, BMI, cardiovascular disease, and diabetes, suggesting that the disparity was not explained by health differences alone.²² For postmenopausal women, hysterectomy is the standard recommendation, so being less likely to receive it translates to a potential delay in definitive diagnosis and treatment. The causes are likely multifactorial, involving differences in referral patterns, insurance coverage, implicit bias, and patient-provider communication. But the finding underscores that a diagnosis of EIN can play out very differently depending on who you are and where you receive care.

Emerging Diagnostic Tools

One of the persistent challenges with EIN is diagnostic reproducibility. Even with the improved EIN criteria, pathologists can still disagree on borderline cases. Artificial intelligence is beginning to enter this space. Researchers have developed deep-learning systems that analyze microscopic images of endometrial tissue to distinguish EIN from benign hyperplasia. One such system, called G2LNet, integrates both broad contextual features and fine-grained cellular textures to screen for precancerous lesions, with the goal of improving both accuracy and efficiency in clinical practice.²³

Another approach uses graph theory, treating individual glands as nodes in a network and analyzing how they relate spatially to one another. The algorithm highlights suspicious gland clusters and overlays them onto the pathologist’s digital display, essentially pointing out areas that warrant closer inspection.²⁴ These tools are not replacing pathologists. They function more like a second set of eyes, flagging areas of concern in a large tissue section that a human reviewer might spend considerable time scanning manually. The technology is still in development, but in a field where diagnostic disagreement can change a patient’s treatment trajectory, even modest gains in consistency could matter.